VanEck Pharmaceutical ETF
PPH
PPH
52 hedge funds and large institutions have $113M invested in VanEck Pharmaceutical ETF in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
52
Holders Change
+2
Holders Change %
+4%
% of All Funds
1.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
14
Reduced
13
Closed
3
Calls
$408K
Puts
$1.65M
Net Calls
-$1.24M
Net Calls Change
-$904K
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$22.8M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$3.62M |
| 3 |
SG Americas Securities
New York
|
+$2.63M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$1.45M |
| 5 |
CCT
Country Club Trust
Kansas City,
Missouri
|
+$890K |
Top Sellers
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.56M |
| 2 |
Morgan Stanley
New York
|
-$1.72M |
| 3 |
Creative Planning
Overland Park,
Kansas
|
-$706K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$688K |
| 5 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$560K |
